Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Average Rating of “Hold” from Analysts

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has been assigned a consensus rating of “Hold” from the seven research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $62.1667.

Several research firms have issued reports on SUPN. Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th.

Supernus Pharmaceuticals Price Performance

SUPN opened at $48.05 on Friday. Supernus Pharmaceuticals has a 12 month low of $31.35 and a 12 month high of $59.68. The stock has a market capitalization of $2.79 billion, a P/E ratio of -94.22, a P/E/G ratio of 1.03 and a beta of 0.54. The business has a 50 day simple moving average of $47.18 and a 200-day simple moving average of $49.50.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. lifted its position in shares of Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 660 shares during the period. Torren Management LLC acquired a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $49,000. EverSource Wealth Advisors LLC acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth approximately $51,000. Hantz Financial Services Inc. increased its stake in Supernus Pharmaceuticals by 73.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Supernus Pharmaceuticals in the 2nd quarter valued at approximately $55,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.